N-{3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(methoxy ethyl)-1H-imidazo[4,5-c]quinolin-7-yl]phenyl}methanesulfonamide | 723264-78-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-{3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(methoxy ethyl)-1H-imidazo[4,5-c]quinolin-7-yl]phenyl}methanesulfonamide
• 英文别名: N-{3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-7-yl]phenyl}methanesulfamide；N-[3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanesulfonamide
• CAS: 723264-78-6
• 化学式: C₂₄H₂₉N₅O₄S
• 分子量: 483.591
• InChiKey: SBHDTQQLGBQXLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  141
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Compounds and compositions for immunotherapy
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US10328158B2

  公开（公告）日：2019-06-25

  The present invention relates to compounds for targeted immunotherapy, as well as compositions comprising the same. Further, the present invention relates to the use of the compounds in the treatment of diseases such as cancer.

  本发明涉及用于靶向免疫疗法的化合物以及包含这些化合物的组合物。此外，本发明还涉及这些化合物在治疗癌症等疾病中的用途。
• Compounds and compositions for treating EGFR expressing tumors
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US10548985B2

  公开（公告）日：2020-02-04

  Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.

  本文提供了用于靶向免疫疗法的化合物。这些化合物可用于治疗表皮生长因子受体表达的肿瘤/癌症。还提供了包含这些化合物的组合物。
• Anti-HER2 combinations for treating tumors
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US11046781B2

  公开（公告）日：2021-06-29

  A combination which comprises an effective amount of Her2/Neu antagonist and an effective amount of immunotherapeutic that is capable of activating a human plasmacytoid dendritic cell, myeloid dendritic cell, NK cell, or a combination thereof is disclosed.

  本发明公开了一种组合物，其中包括有效量的 Her2/Neu 拮抗剂和有效量的能够激活人类浆细胞树突状细胞、髓样树突状细胞、NK 细胞或其组合的免疫疗法。
• Anti PD-L1 conjugates for treating tumors
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US11130812B2

  公开（公告）日：2021-09-28

  The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.

  本发明公开了用于靶向免疫疗法的抗-PD-L/PD-1 轴抗体共轭物以及包含上述共轭物的组合物。此外，本发明还公开了共轭物在治疗肿瘤/癌症中的用途。
• Anti-EGFR combinations for treating tumors
  申请人：BIRDIE BIOPHARMACEUTICALS, INC.

  公开号：US11136397B2

  公开（公告）日：2021-10-05

  The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

  本发明涉及治疗组合以及使用组合疗法治疗癌症的方法。